title: Effects of selective phosphodiesterase inhibitors on the polymorphonuclear leukocyte respiratory burst.
abstract: Modulation of the human polymorphonuclear leukocyte (PMN) respiratory burst by selective cyclic 3',5' adenosine monophosphate (cAMP) phosphodiesterase (PDE) inhibitors was studied with respect to PDE isozyme characteristics. Zaprinast, an inhibitor of a cyclic guanosine monophosphate (cGMP)-specific PDE (PDE I), at concentrations up to 100 mumol/L, had no significant effect on the respiratory burst. Milrinone and imazodan, inhibitors of cAMP-metabolizing, cGMP-sensitive PDE (PDE III), reduced the respiratory burst to 60% of control magnitude but only had significant effects when they were introduced at high (100 mumol/L) concentrations. In contrast, rolipram and RO 20-1724, inhibitors of a cAMP-metabolizing, cGMP-insensitive PDE (PDE IV), had significant effects at low concentrations (0.1 mumol/L) and caused marked reduction of the respiratory burst at higher concentrations (25% of control at 10 mumol/L). The selective PDE IV inhibitors significantly potentiated PMN inhibition by isoproterenol. Diethylaminoethyl (DEAE)-Sepharose chromatography demonstrated a predominant PDE isozyme with high affinity and selectivity for cAMP that was insensitive to cGMP and was completely inhibited by rolipram, a PDE IV inhibitor. These results are consistent with the conclusion that the PMN respiratory burst is inhibited by an elevation of cAMP induced by PDE IV inhibition.
authors.affiliation: Clinical Pharmacology and Gerontology Research Unit, Veterans Administration Medical Center, Boise, ID 83702.
authors.forename: C P
authors.initials: CP
authors.lastname: Nielson
authors.forename: R E
authors.initials: RE
authors.lastname: Vestal
authors.forename: R J
authors.initials: RJ
authors.lastname: Sturm
authors.forename: R
authors.initials: R
authors.lastname: Heaslip
mesh_terms: D012368:4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone / Q000494:pharmacology; D000318:Adrenergic beta-Agonists / Q000494:pharmacology; D000328:Adult; D000001:Calcimycin / Q000494:pharmacology; D002852:Chromatography, Ion Exchange; D006801:Humans; D007527:Isoenzymes / Q000302:isolation & purification; D007545:Isoproterenol / Q000494:pharmacology; D008875:Middle Aged; D020105:Milrinone; D009504:Neutrophils / Q000187:drug effects* / Q000201:enzymology; D010101:Oxygen Consumption / Q000187:drug effects*; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology*; D010727:Phosphoric Diester Hydrolases / Q000302:isolation & purification / Q000378:metabolism; D011688:Purinones / Q000494:pharmacology; D011724:Pyridazines / Q000494:pharmacology; D011728:Pyridones / Q000494:pharmacology; D011760:Pyrrolidinones / Q000494:pharmacology; D020889:Rolipram; D013481:Superoxides / Q000378:metabolism
chemical_list: D000318:Adrenergic beta-Agonists; D007527:Isoenzymes; D010726:Phosphodiesterase Inhibitors; D011688:Purinones; D011724:Pyridazines; D011728:Pyridones; D011760:Pyrrolidinones; D013481:Superoxides; D012368:4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone; D000001:Calcimycin; C042527:imazodan; D010727:Phosphoric Diester Hydrolases; C011145:zaprinast; D020105:Milrinone; D020889:Rolipram; D007545:Isoproterenol